Dacomitinib
| Use attributes for filter ! | |
| Bioavailability | 80% |
|---|---|
| Protein binding | 98% |
| Other names | PF-00299804 |
| Trade name | Vizimpro |
| ATC code | L01XE47 (WHO) |
| License data | US |
| DailyMed | |
| Music groups | Osimertinib |
| Afatinib | |
| Gefitinib | |
| Erlotinib | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951313 |
About Dacomitinib
Dacomitinib is a drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma. It is a selective and irreversible inhibitor of EGFR. Dacomitinib has advanced to several Phase III clinical trials.
